Dear Reader,

As we reach the final issue of Drugs in R&D for 2017, we wish to reflect on another successful year's achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content.

2017 was a successful year for Drugs in R&D with over 60 articles published.

The quality of articles published in the journal is also reflected in its most recent Scimago 2-year citations per document value of 2.139. The journal was also included this year in the Emerging Sources Citation Index from Clarivate Analytics.

Other journals in the Adis Premier Journals Portfolio (<http://www.springer.com/gp/adis>) continue to prosper, and this year has seen the successful launch of *PharmacoEconomics - Open*, the newest journal in the portfolio. The journal has published a full volume of 30 articles in its first year, plus many more online first. Following in the steps of Adis' flagship subscription journal in the field, *PharmacoEconomics*, the new open-access journal focuses on cost and health outcomes associated with drugs, devices and other healthcare interventions.

We thank the authors who have contributed articles to Drugs in R&D over the course of 2017. The skill and dedication of all authors are critical to the continued publication of the journal. The quality of published articles is also testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal's content is held to the highest possible standard. We would like to thank the following individuals who acted as reviewers for Drugs in R&D in the last 12 months:
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*G. Borasi*, UK

*P. K. Borkowski*, Poland

*A. Braddy*, USA

*S. Chirumbolo*, Italy

*C. Comacchio*, Italy

*D. Crawford*, USA

*R. Crazzolara*, Austria

*M. Gomes Davanço*, Brazil

*A. Di Paolo*, Italy

*L. Endrenyi*, Canada

*C. Engelmann*, Germany

*P. Fagiolino*, Uruguay

*J. Gailer*, Canada

*A. Gaweda*, USA
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*Y. Higashi*, Japan
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*P. Janssen*, The Netherlands
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*J. Livezey*, USA
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In addition, we would like to thank the members of the journal's Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:
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We do hope that you have found the articles published throughout the year in Drugs in R&D to be interesting and informative. The editorial schedule for 2018 is well under way, and we are looking forward to bringing you many high-quality and authoritative articles over the coming year.

With best wishes, Anton van Rensburg
